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Introduction
The recent technical developments in computed tomog-
raphy (CT), magnetic resonance imaging (MRI) and 
nuclear medicine have changed the role of imaging in the 
evaluation of children with cancer revolutionary [1, 2]. In 
the past, imaging techniques have been mainly used as a 
tool to detect tumours and to assess the extent of tumour 
spread before and after therapy (i.e., structural imaging). 
But nowadays, it has also become possible to use imaging 
techniques to gain information on the biological behav-
iour of the tumour before and during therapy (i.e., func-
tional imaging). Until recently, CT has been the structural 
imaging technique of choice for staging and follow-up 
of malignancies. The functional imaging techniques that 
play a central role in paediatric cancer imaging include 
positron emission tomography (PET) using the radiotracer 
[18F]-2-fluoro-2-deoxy-d-glucose (FDG), and single-pho-
ton emission computed tomography (SPECT) using the 
radiotracer Iodine-123 metaiodobenzylguanidine (I-123 
MIBG). These functional imaging techniques are usually 
combined with CT (i.e. PET/CT and SPECT/CT) allow-
ing for defining anatomic localisation, lesion characteriza-
tion, segmentation, and quantification of areas with abnor-
mal tracer uptake in a single visit. A major disadvantage of 
all these techniques is the use of ionising radiation, which 
may be associated with induction of second cancers later 
during life. This small but not negligible health risk is of 
particular concern in children as their tissues are more radi-
osensitive than adults and they have more years ahead in 
which cancerous changes might occur. That is why there 
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is an increasing interest in the use of alternative imaging 
techniques that do not use ionising radiation, such as ultra-
sonography (US) and MRI [1].
Although US is a child-friendly imaging technique that 
can provide real-time detailed images of most body parts, 
it is less useful for the evaluation of large masses, extended 
disease, deeper-lying tissues, and tissues located behind 
bones and air-containing tissues. That is why the main role 
of US in cancer imaging is to help ascertain the nature of 
palpable masses and to guide biopsy procedures. On the 
other hand, with MRI it is possible to acquire images with 
a high spatial resolution and excellent soft tissue contrast 
throughout the body, which makes it an ideal radiation-free 
tool for the detection of pathology, especially in parenchy-
mal and bone marrow locations. Moreover, recent techno-
logical advances have resulted in fast diagnostic sequences 
for whole-body MR imaging (WB-MRI), including func-
tional techniques such as diffusion weighted imaging 
(DWI) [3–10]. As a result, WB-MRI has become a clini-
cally feasible imaging modality for staging and follow-up 
of malignancies in children [11–14]. This review will focus 
on the current status of the technique and major clinical 
applications of WB-MRI in children with cancer.
Technique
Until now, there is no standardised technique or protocol 
for performing WB-MRI [3, 6]. It usually involves imaging 
of the entire body (from vertex to toes) but in oncology, it 
is often restricted to the skull or skull base to groin region 
in line with most hybrid imaging techniques. Most mod-
ern MRI scanners are equipped with a moving table top 
for sequential movement of the patient through the magnet 
during imaging without the need for repositioning.
Regarding the choice of coils, the use of phased-array 
surface coils is preferred over the use of the quadrature 
body coil integrated in the magnet bore, because of the 
better spatial resolution and signal-to-noise ratio (SNR) 
of the first over the latter. This is especially true when 
functional imaging techniques like DWI are planned to 
be included in the imaging protocol. The way these coils 
can be used for whole-body image acquisition depends 
on the type of MRI scanner available. One approach, the 
so-called “sliding table and repositioning surface coil” 
approach, uses tabletop spacers to place an additional 
table platform on the original MR table allowing manipu-
lation of the lower part of a non-integrated phased-array 
surface coil without repositioning the patient [15]. How-
ever, nowadays, on several modern MRI scanners dedi-
cated multichannel surface coil systems are available 
allowing for whole-body imaging without the need to 
reposition the coil at each station [6].
Sequences that are typically used in WB-MRI include 
short tau inversion recovery (STIR), T1-weighted fast spin 
echo (FSE, TSE), and contrast material-enhanced (CE) 
T1-weighted three-dimensional gradient echo (VIBE, 
THRIVE, LAVA) sequences. STIR is the most commonly 
used sequence in WB-MRI because most pathologic tissues 
are proton rich with prolonged T1 and T2 relaxation times 
resulting in high signal intensity on STIR images. Further-
more, fat suppression on STIR images is more robust and 
homogeneous than on T2-weighted fat-saturated images. 
The T1-weighted FSE sequence is especially helpful for 
anatomic delineation of lesions and to increase the speci-
ficity of the detection of bone marrow involvement. The 
addition of a 3D CE T1-weighted GRE sequence will often 
improve the diagnostic accuracy of lesion delineation and 
characterization. Furthermore, it facilitates the combination 
of better local tumour staging and evaluation of metastatic 
disease.
With the introduction of diffusion-weighted whole-
body imaging with background body signal suppression 
(DWIBS) in 2004 by Takahara et al., it became possible 
to perform whole-body DWI under free breathing within 
a clinically acceptable examination time [5, 7, 16, 17]. To 
improve lesion conspicuity high b-values of up to 1000 s/
mm2 are applied and either a STIR pre-pulse or a frequency 
selective (chemical shift selective, CHESS) pre-pulse is 
used for fat suppression to optimise background body sig-
nal suppression. Note that fat suppression is also required 
to avoid image degradation due to severe chemical shift 
when using EPI. The choice of the method of fat suppres-
sion may depend on the organ/body region under examina-
tion, although STIR usually results in the most robust fat 
suppression over an extended field of view, in particular in 
the neck/shoulder region and lower extremities. In addition, 
if bowel signal suppression is an important issue, STIR is 
the preferred method in the abdominal region as well. In 
case quantitative measurements of the diffusivity (appar-
ent diffusion coefficient, ADC) in pathological tissues are 
required, the use of at least three b-values is recommended 
(including b0).
The choice of scan plane will depend on the region 
of interest, type of malignancy, and diagnostic informa-
tion required for optimal treatment planning and follow-
up. However, the coronal plane is most often acquired 
and displayed in whole-body imaging, in particular when 
STIR and T1-weighted FSE sequences are used. The 3D 
CE T1-weighted GRE and DWIBS sequences are usually 
acquired in the axial plane, but the obtained images can 
be easily post-processed for multiplanar reconstruction 
(MPR) and maximum intensity projection (MIP). MRI of 
the thoracic and abdominal part of the body is challeng-
ing because of movement of patient respiration and bowel 
peristalsis. The anatomical imaging of thorax and abdomen 
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is usually obtained using respiratory compensation tech-
niques, whereas the DWIBS imaging will take place under 
free breathing. To reduce the bowel motility, intravenously 
injection of an antiperistaltic agent can be considered, such 
as hyoscine butylbromide or glucagon. This is especially 
relevant if the abdomen is the site or predisposed area of 
the (known or suspected) primary malignancy.
In Tables 1 and 2 examples are given of two different 




Bone marrow has three primary components: osseous 
matrix, red marrow and yellow marrow. The osseous com-
ponents provide supporting framework to the red and yel-
low marrow elements. The red marrow is composed of 
haematopoietic cells that produce the peripheral blood pre-
cursors, whereas in yellow marrow fat cells make up the 
vast majority. The distribution of haematopoietic marrow 
and its cellular content vary with age. At birth, marrow is 
entirely haematopoietic. Shortly after birth, the transition 
to yellow bone marrow occurs at an orderly and predict-
able sequence, which begins in the peripheral bones and 
progresses in a symmetrical manner to the central skeleton. 
Within the individual long bones, the marrow conversion 
occurs first in the diaphysis that progresses to the metaphy-
sis. In the first decade of life the vertebral marrow is pre-
dominantly haematopoietic except for some yellow bone 
marrow around the central vertebral vein [18].
MRI is a sensitive method for assessing bone marrow; 
however, it lacks specificity. Normal bone marrow is rich 
in fat and water that together contribute to the signal seen 
on MRI. Red marrow contains approximately 40 % fat and 
40 % water whereas yellow marrow is composed of approx-
imately 80 % fat and 15 % water. TSE sequences allow 
superb differentiation between red and yellow bone marrow 
as the signal characteristics of fatty and hematopoietic mar-
row are different. However, the T1-weighted sequence will 
detect all the fat in the marrow inclusive the 40 % fat that 
is present in the hematopoietic marrow. Therefore, hemat-
opoietic marrow is slightly hyperintense to normal muscles 
and the intervertebral discs of the spine (Fig. 1b). On water 
sensitive images (i.e. STIR) hematopoietic marrow is of 
higher signal intensity than fatty marrow [3, 9].
Malignant infiltration of the bone marrow is associated 
with free water and oedema in addition to replacement of 
Table 1  WB-MRI protocol—lymphoma (1.5T, Ingenia, Philips Healthcare, Best, The Netherlands)
Parameter Pulse sequence
T1-weighted TSE STIR DWI-STIR T2-weighted SPAIR
Repetition time (ms) 583 5231 8046 1250
Echo time (ms) 18 65 67 80
Inversion time (ms) – 165 180 –
Receiver bandwidth (Hz) 465.9 502.7 57.3 647.0
Slice orientation Coronal Coronal Axial Axial
Slice thickness (mm) 6.0 6.0 4.0 6.0
Slice gap (mm) 1.0 1.0 0 0.7
No. of slices per station 30 30 60 36
Cranio-caudal coverage per station 265 265 240 240
Field of view (mm2) 530 × 265 530 × 265 450 × 365.625 450 × 366.4286
Acquisition matrix 208 × 287 336 × 133 128 × 82 280 × 202
B-values (s/mm2) – – 0, 100, 800 –
No. of signal averaged 1 1 1 1
Echo-planar imaging factor – – 41 –
Respiratory motion compensation tech-
nique
Breath hold in thorax  
and abdomen
Breath hold in thorax  
and abdomen
Free breathing Free breathing
Acquired voxel size (mm3) 1.27 × 1.85 × 6.00 1.58 × 1.98 × 6.00 3.52 × 4.46 × 4.00 1.61 × 1.81 × 6.00
Reconstructed voxel size (mm3) 1.04 × 1.04 × 6.00 1.04 × 1.04 × 6.00 2.01 × 1.99 × 4.00 0.94 × 0.93 × 6.00
Effective scan time per station 54 s 1 min 45 s 4 min 45 s
Total number of stations 5 5 4 4
Total effective scan time 4 min 30 s 8 min 45 s 16 min 3 min
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the fatty content of normal marrow. Therefore, pathologi-
cal bone marrow is of low T1 and high T2 signal (Fig. 1a). 
Especially in young patients it can be challenging to detect 
bone marrow disease, because the high cellularity of nor-
mal red marrow can be misdiagnosed as diffuse bone mar-
row infiltration or mask tumour deposits. Chemical shift 
imaging (oppose phase imaging) could be used as a com-
plementary tool in order to differentiate between malignant 
bone marrow infiltration and normal red marrow by detect-
ing small quantities of fat. Previous studies have shown that 
chemical shift imaging allows distinction between benign 
and malignant causes in adult patients [19, 20].
DWI in assessment of bone marrow disease is, espe-
cially in young patients, of limited value, as the high cel-
lular haematopoietic marrow will exhibit impeded diffu-
sion. Ording-Müller et al. [21] demonstrated that areas of 
restricted diffusion in the pelvic skeleton and lumbar spine 
are a normal finding in 48 % of healthy children. Therefore, 
DWI, if used in isolation, could increase the false-positive 
rate of bone marrow pathology.
Meyer et al. [22] tried to identify the best MRI sequence 
or image criteria for the diagnosis of bone marrow metas-
tases in children with neuroblastoma. They found that 
homogenous low T1 signal had the highest sensitivity 
(88 %), whereas a heterogeneous pattern on the post-gado-
linium was highly specific (97 %), but relatively insensitive 
(65 %) for detecting metastasis.
Malignant lymphoma
Lymphoma [Hodgkin Disease (HD) and non-Hodgkin lym-
phoma (NHL)] is the third most common form of malig-
nancy in children, after leukaemia and brain tumours [23]. 
NHL is most frequent in children younger than 15 years 
Table 2  WB-MRI protocol—neuroblastoma (1.5T, Ingenia, Philips Healthcare, Best, The Netherlands)
Parameter Pulse sequence
3D T2W TSE T1 THRIVE DWI T1 TSE (spine) STIR (spine) T1 THRIVE Gd
Repetition time (ms) 454 5.5 1341 550 2000 5.5
Echo time (ms) 90 2.7 73 8.0 60 2.7
Inversion time (ms) – – – – 180 –
Receiver bandwidth 
(Hz)
570.1 309.6 47.9 206.1 383.0 309.6




Slice gap (mm) 0 0.3 0.3
No. of slices per 
station
139 85 26 15 15 85
Cranio-caudal cov-
erage per station
400 127.5 130 449.1228 448 127.5
Field of view (mm2) 400 × 354.023 250 × 189.2759 250 × 250 449.1228 × 160 448 × 160 250 × 189.2759
Acquisition matrix 348 × 308 232 × 185 88 × 70 228 × 494 160 × 381 232 × 185
B-values (s/mm2) – – 0, 100, 1000 – – –
No. of signal aver-
aged
1 4 1 2 2 4
Echo-planar imag-
ing factor






Free breathing Respiratory  
triggered
Free breathing Free breathing Free breathing
Acquired voxel size 
(mm3)
1.15 × 1.15 × 1.15 1.08 × 1.07 × 3.00 2.84 × 3.57 × 5.00 0.70 × 0.91 × 3.00 1.00 × 1.17 × 3.00 1.08 × 1.07 × 3.00
Reconstructed voxel 
size (mm3)
0.83 × 0.83 × 1.15 0.74 × 0.74 × 1.50 1.74 × 1.74 × 5.00 0.47 × 0.47 × 3.00 0.70 × 0.70 × 3.00 0.74 × 0.74 × 1.50
Effective scan time 
per station
4 min 09 s 2 min 1 min 48 s 5 min 10 s 4 min 2 min
Total number of 
stations
1 3 3 1 1 3
Total effective scan 
time
4 min 09 s 6 min 5 min 24 s 5 min 10 s 4 min 6 min
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whereas HD is predominantly diagnosed in teenagers. A 
major challenge in treating paediatric lymphoma is to opti-
mise up-front treatment to prevent disease relapse, while 
minimising late therapy-related side effects. Accurate 
assessment of disease extent at diagnosis and response to 
treatment are therefore essential. Paediatric lymphomas are 
staged using the modified Ann Arbor and Murphy classifi-
cations for HD and NHL, respectively [24, 25].
Current guidelines encourage the use of FDG-PET/CT 
in staging and response assessment of FDG-avid lympho-
mas [24]. WB-MRI could be a good radiation-free alterna-
tive for staging and follow-up. Several studies have shown 
that WB-MRI is feasible, even in children (Fig. 2) [26–28]. 
Punwani et al. [27] reported very good agreement between 
WB-MRI compared to an FDG-PET/CT reference standard 
for nodal and extranodal disease, despite only using STIR 
for whole-body imaging.
There is an increased interest for the use of DWI in lym-
phoma due to the clear visualisation of the lymphoid tis-
sue with DWI that is thought to increase the detection rate 
while decrease reading time. Lin et al. [29] showed an 
excellent agreement between WB-DWI and FDG-PET/CT 
in 15 adult patients with diffuse large B cell lymphomas. 
However, in other studies the additional value of DWI to 
conventional sequences could not be demonstrated [28, 30]. 
This could be related to the fact that both benign and malig-
nant nodes demonstrate impeded diffusion. Also, there are 
no validated ADC values yet for discriminating involved 
from not involved sites [30]. Therefore, the detection of 
lymph nodes in WB-DWI is still based on size criteria. An 
important issue with DWI is that several normal extran-
odal structures (including brain, salivary glands, Waldeyer 
ring, thymus, spleen, gallbladder, adrenal glands, prostate, 
testes, penis, endometrium, ovaries, spinal cord, peripheral 
nerves and bone marrow) may demonstrate impeded diffu-
sion. Consequently, pathology in any of these areas may be 
obscured.
Klenk et al. [14] prospectively compared Ferumoxytol-
enhanced whole-body diffusion-weighted MRI to FDG-
PET/CT in 22 children and young adults for staging lym-
phoma and sarcoma. This iron oxide contrast is thought 
to overcome the limitations of conventional WB-MRI 
regarding detecting bone marrow and splenic involvement. 
This better detection of lymphomatous involvement in the 
reticuloendothelial system (RES) depends on the uptake of 
USPIO through macrophages in the non-involved RES and 
the non-uptake by metastatic tumour deposits.
Assessment of response to therapy is important for 
determining treatment effectiveness and predicting clini-
cal outcome. The concept of early response assessment 
Fig. 1  Sagittal T1 spin echo (SE) image in two patients diagnosed 
with neuroblastoma. a The image of a 3-year-old girl with proven 
bone marrow involvement illustrate the diffuse low signal intensity of 
the bone marrow of the spine compared to the intervertebral disk that 
is suggestive for diffuse bone marrow infiltration, whereas normal 
hematopoietic bone marrow is slightly hyperintense to the interver-
tebral discs of the spine at T1 weighted imaging. b The image of a 
2-year-old girl with thoracic neuroblastoma shows the appearance of 
not-involved bone marrow within the vertebral bodies. c Transverse 
T2-W image demonstrates the intraspinal extension with spinal cord 
compression (arrow, see also the arrow in b) as well as the vascular 
encasement and the lifting of the aorta (arrowheads) that is consid-
ered one of the key imaging features of neuroblastoma
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with FDG-PET/CT in lymphoma has received considerable 
attention last years, however it is still not officially recom-
mended outside clinical trails [24]. The role of WB-MRI 
in response assessment in children with lymphoma is still 
under investigation. Mayerhoefer et al. [31] recently pub-
lished their results of their prospective study in 64 adult 
lymphoma patients that showed that WB-MRI with DWI 
could serve as a feasible alternative for FDG-PET/CT dur-
ing follow-up and treatment response assessment. Sev-
eral, mostly pilot, studies compared the quantitative data 
from FDG-PET/CT (SUV) with DWI (ADC values) for 
interim response assessment with inconclusive results. 
They reported presence or absence of an inverse correlation 
between ADC and SUV [32–35].
Although FDG-PET/CT is the imaging technique of 
choice for treatment response assessment, the value of 
interim and end-of-treatment FDG-PET/CT in predicting 
outcome was demonstrated to be unsatisfactory by recent 
meta-analyses [36, 37]. Therefore, prospective studies 
that correlate DWI results with patient outcome measures 
instead of FDG-PET/CT will provide reliable evidence.
Histiocytosis
Langerhans cell histiocytosis (LCH) is a rare disease that 
is characterised by lesions that include CD207+ dendritic 
cells with phenotypic similarity to epidermal Langerhans 
cells on a background of inflammatory cells [38]. The 
incidence of LCH is approximately 5:1,000,000 children 
younger than 15 years of age with an equal distribution 
among boys and girls. The median age of presentation is 
30 months. LCH can involve almost any organ, and the 
most common presentation includes skin rashes and/or 
painful bone lesions. Less frequently, children present with 
diabetes insipidus due to pituitary involvement or back pain 
caused by vertebra plana. For prognostic purposes, patients 
are usually divided into a clinical “high-risk” versus “low-
risk” group, based on the presence or absence of liver, 
spleen and/or bone marrow involvement. “High-risk” LCH 
patients have a >85 % long-term survival rate, whereas the 
survival rate of “low-risk” LCH patients approaches 100 %.
Adequate staging at diagnosis is essential, not only for 
determining prognosis, but also for choice of therapy, as 
lesions in more than one site usually impact the need for 
systemic chemotherapy. The standard approach to stag-
ing usually consists of a combination of laboratory tests 
and imaging [38, 39]. Traditionally, the imaging evalu-
ation of patients with LCH includes chest radiography 
and a complete skeletal survey. Nowadays an abdominal 
ultrasound is usually added to rule out/demonstrate intra-
abdominal organ involvement. Skeletal involvement is the 
most common radiographic abnormality in LCH. Primary 
sites of bony involvement are the skull, ribs, spine (verte-
bra plana), pelvis and scapula. The long bones are less fre-
quently involved, with the femora as the most commonly 
involved long bone. Extension of the primary bony lesion 
in the surrounding soft tissues and epidural space can be 
seen, especially in the skull, ribs and spine. Bone scintigra-
phy has been used for the evaluation of LCH, and although 
lesion detection is usually higher when compared to the 
skeletal survey, the scintigraphic appearance of LCH may 
vary especially when the lesions are small or fail to incite a 
significant osteoblastic response [39, 40]. The use of 18F-
FDG PET for the evaluation of paediatric LCH has been 
Fig. 2  Coronal whole-body 
short tau inversion-recovery 
(a), T1-W (b) and maximum 
intensity projection greyscale 
inverted diffusion-weighted 
(c) images of a 12-year-old 
boy with anaplastic large cell 
lymphoma illustrate nodal 
involvement at both sides 
of the diagram (arrows) and 
an enlarged spleen (splenic 
index 763 cm3) indicating 
splenic involvement diagnosed 
with whole-body MRI. The 
paraaortal and left parailiacal 
involvement as illustrated at the 
diffusion-weighted image is not 
seen at the coronal STIR and 
T1-W images as this area was 
not included in these slices
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reported, and several recent studies have shown high sen-
sitivity and specificity of this imaging technique superior 
to the skeletal survey and bone scintigraphy [41]. In addi-
tion, 18F-FDG PET allows for the identification of extra-
osseous localisations of LCH and shows lesion response 
to therapy earlier than conventional radiography and CT. 
However, a recent study by Mueller et al. [41] also showed 
that the overall sensitivity of 18F-FDG PET was lower than 
WB-MRI, especially for small bony infiltrates (mean diam-
eter 12 mm), and central nervous system involvement. As 
stated before, WB-MRI is very well suited for the evalu-
ation of bone marrow involvement, accompanying soft-
tissue masses, and other extra-osseous manifestations. In 
LCH, most bony lesions will show intermediate–hypoin-
tense signal on T1-weighted images and hyperintense sig-
nal on T2-weighted and STIR images (Figs. 3, 4) [42, 43]. 
On postcontrast T1-weighted images the LCH lesions usu-
ally show marked enhancement although predominantly 
peripheral enhancement can be seen. In addition, early-
stage lesions will show oedema in the adjacent bone mar-
row, periosteum and soft tissues. Direct extension in the 
adjacent soft tissues and epidural space is very well appre-
ciated with MRI. The same holds true for the extra-osseous 
organ involvement. During treatment, healing lesions will 
show decrease in signal intensity on STIR imaging. Unfor-
tunately, large prospective studies on the diagnostic accu-
racy of WB-MRI in paediatric LCH are missing. Goo et al. 
[42] compared the use of WB-MRI to conventional radiog-
raphy and bone scintigraphy in 9 children with LCH. Addi-
tional skeletal lesions were identified by WB-MRI in 3 out 
of 8 patients compared with plain radiography (38 %), and 
in 2 out of 8 patients compared with scintigraphy (25 %). 
Furthermore, WB-MRI detected extra-osseous lesions in 
5 of nine patients exclusively (56 %). Steinborn et al. [43] 
did investigate the use WB-MRI in 6 children with LCH 
at diagnosis and during follow up. In comparison with 
the skeletal survey, WB-MRI did detect additional lesions 
in two patients, which resulted in a change of therapy in 
both children. On the other hand, Mueller et al. [41] did 
show that, although WB-MRI was more sensitive for the 
detection of LCH lesions when compared 18F-FDG-PET, 
specificity was significantly lower (67 and 76 % for PET 
Fig. 3  14-year-old male with 
Langerhans cell histiocyto-
sis (LCH) presenting with a 
painless swelling on the skull. 
Axial proton density weighted 
image (a), T2-weighted image 
(b), and sagittal T1-weighted 
images before (c) and after the 
administration of intravenous 
contrast material (d). The lesion 
shows almost homogeneous 
T2 hyperintensity and slightly 
heterogeneous T1 intermediate 
signal intensity (arrow in a–c). 
After contrast material adminis-
tration there is a predominantly 
peripheral enhancement pattern, 
less often seen in LCH lesions 
(arrow in d)
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vs. 81 and 47 % for WB-MRI). The lower specificity of 
WB-MRI was mainly due to the detection of false-positive 
bone lesions. Furthermore, residual T2 hyperintensity and 
contrast-enhancement after treatment on WB-MRI resulted 
in false-positive findings during follow-up. Interestingly, a 
combined analysis of PET and MRI decreased the number 
of false-negative findings at primary staging, whereas no 
advantage over PET alone was seen in terms of false-pos-
itive or false-negative results during follow-up.
Neuroblastoma
Neuroblastoma (NBL) is the most common solid extra-cra-
nial tumour in children and infants. It represents approxi-
mately 6 % of all cases of childhood cancer and accounts 
for 15 % of cancer deaths in children [23]. NBL is an 
embryonic tumour arising from primordial neural crest 
cells that are the precursors of the sympathetic nervous 
system. The most common site of the primary tumour is 
within the abdomen (the adrenal medulla in 35 %), but it 
can occur anywhere along the sympathetic chain from neck 
to pelvis [44]. Nearly 70 % of children with NBL will have 
metastatic disease at diagnosis (cortical bone, bone mar-
row, lymph nodes, liver and skin). NBLs have a variable 
prognosis. Some tumours behave aggressively, while oth-
ers, often in the younger age group, may spontaneously 
regress [44].
Ninety percentage of patients are diagnosed before the 
age of 6, with a peak incidence around 2–3 years [44]. 
Clinical presentation varies with the size, spread and loca-
tion of the tumour in often an unwell child. In the abdo-
men it can cause abdominal distension, sometimes nausea 
or pain. Unexplained fevers, bone pain or limping is caused 
by bone or bone marrow involvement. If the tumour is com-
pressing the spinal cord it causes muscle weakness or prob-
lems with urinating or defecation. Some tumours produce 
hormones that can cause high blood pressure, increased 
heart rate, flushing or diarrhoea.
Since 1986, the International Neuroblastoma Staging 
System (INSS) has been used as a post-surgical staging 
system. In 2009 a new staging system was published [the 
International Neuroblastoma Risk Group Staging System 
(INRGSS)], shifting focus to pre-treatment staging with 
identification of imaging defined risk factors (IDRF) [45]. 
These IDRFs describe the relationship between the tumour 
and adjacent structures that ideally should not be injured 
during surgery (i.e., major vascular encasement, airway 
compression or CNS infiltration).
The combination of nuclear medicine and radiologi-
cal examinations are crucial for accurate staging, defining 
resectability and follow-up during treatment. Traditionally, 
CT, I-123 MIBG scintigraphy and bone marrow biopsies 
were used to evaluate the local and distant extend of dis-
ease. However, MRI is increasingly used for anatomical 
Fig. 4  A 7-year-old girl with Langerhans cell histiocytosis (LCH) 
presenting with back pain. Sagittal T2-weighted (a), STIR (b), 
T1-weighted (c), and contrast-enhanced fat saturated T1-weighted (d) 
images of the spine showing involvement of multiple vertebral bodies 
(small arrows) as well as a “vertebra plana” at the level of Th3 (large 
arrow). The lesions are best seen on the precontrast T1-weighted and 
T2-weighted images
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imaging (Fig. 5) [44]. The impact of WB-MRI in neuro-
blastoma has not been thoroughly evaluated. Pluger et al. 
[46] retrospectively reviewed 50 MRI and I-123 MIBG 
examinations in 28 patients for the assessment of neuro-
blastoma lesions at presentation and follow-up. They con-
cluded that integrated imaging with I-123 MIBG scintig-
raphy and MRI increased the diagnostic accuracy. Gahr 
et al. [47] studied the role of DWI in differentiating neu-
roblastoma and ganglioneuroblastoma/ganglioneuroma 
in 15 patients with 16 histologically classified tumours. 
They found that there was a significant difference in ADC 
between neuroblastoma and ganglioneuroblastoma/gangli-
oneuroma. However, the inter- and intraobserver variability 
of their applied method was not tested. Besides, there was a 
considerable overlap in ADC values between these groups.
Cancer predisposition syndromes
WB-MRI is a promising imaging tool in the evaluation of 
genetic cancer predisposition syndromes (CPS), especially 
because of its lack of ionising radiation [48, 49]. Children 
with CPS (including neurofibromatosis type 1, Beckwith-
Wiedemann, multiple endocrine neoplasia, Li-Fraumeni, 
Von Hippel-Lindau, and rhabdoid tumour syndrome) are 
at a significantly increased risk of developing cancer, but 
when and in which organs tumours will develop is diffi-
cult to predict. Therefore, screening on a regularly basis is 
usually recommended in these children, the frequency of 
which depends on the specific syndrome and risk stratifi-
cation. Several publications already did mention the use of 
WB-MRI as a screenings method in CPS, but studies on the 
performance of this technique in children is scarce. Fried-
man et al. [48] retrospectively investigated the role of WB-
MRI as a screening tool in follow-up of children and ado-
lescents with hereditary retinoblastoma. WB-MRI detected 
suspicious lesions in 5 of 25 patients during follow-up of 
which only 2 appeared to be malignant (osteosarcoma). 
One additional patient was diagnosed with osteosarcoma 
3 months after a normal WB-MRI. The sensitivity of WB-
MRI to detect subsequent malignant lesions in this spe-
cific patient group was 66.7 % and the specificity 92.1 %. 
Another recent (retrospective) study, which included 50 
WB-MRI examinations in 24 children with genetic CPS, 
did show that WB-MRI is a valuable screening tool with 
a high sensitivity of 100 % (95 % CI 6–100 %), specificity 
of 94 % (82–98 %), and negative predictive value of 94 % 
(90–100 %) [49]. In nine of the 50 WB-MRI examinations 
a suspicious lesion was found; 2 high-risk, 2 moderate-
risk, and 5 low-risk lesions. Of the 4 high- to moderate-risk 
lesions, only one lesion appeared to be malignant result-
ing in a positive predictive value of only 25 % (95 % CI 
1–78 %). The other lesions and all low-risk lesions had 
a benign origin. Of interest, this study did also show that 
incidental findings were detected in 23 of 24 patients, most 
of which did not require imaging follow-up. Finally, all 
abnormalities were best detected on the (fluid-sensitive) 
STIR images. The role of DWI has not been investigated. 
Both studies conclude that, although WB-MRI can be 
regarded as a valuable screening tool, larger cohort stud-
ies are needed to validate its role and cost-effectiveness in 
this specific group of patients. Furthermore, Anupindi et al. 
[49] recommend that interpretation of these studies should 
be reserved to radiologists that are familiar with WB-MRI 
to appropriately risk stratify abnormalities and minimise 
unnecessary interventions.
Future perspectives
In children, the choice of imaging modality is driven 
mainly by reducing the radiation dose as much as possible. 
This also accounts for children with cancer, as their over-
all survival rates have increased significantly over the past 
decades. This explains the increasing interest for the use of 
(whole-body) MRI in the diagnostic work-up and follow-up 
of children with cancer. As illustrated in this review, WB-
MRI is already widely used in paediatric oncology, despite 
the fact that validation of the technique is mainly based on 
retrospective data in relatively small patient groups. There 
is a strong need for large prospective cohort studies to bet-
ter validate the role and cost-effectiveness of WB-MRI in 
children with cancer, both for diagnosis as well as therapy 
response assessment. However, due to the comparatively 
low incidence of most paediatric malignancies, most insti-
tutions will not have sufficient patient volume to perform 
clinical trials that will result in definitive and statistically 
significant data. This obviates the need for increasing inter-
national multi-institutional collaboration and set up of mul-
ticentre clinical trials [50].
In oncology, the role of imaging is moving from struc-
tural (anatomic) imaging to combined structural and func-
tional (molecular) imaging, enabling better tumour char-
acterization, prognostication, response assessment, and 
prediction of outcome of therapy. That is why research 
on WB-MRI in children not only should focus on further 
optimization of anatomic sequences (including reduction 
of scan duration) but also on the introduction and valida-
tion of new functional techniques. DWI is already widely 
used, but the value of DWI and ADC measurements in 
diagnosis and follow up still has to be validated. Other 
functional techniques focus on tumour vascularisation, 
such as dynamic contrast-enhanced MRI (DCE-MRI) and 
arterial spin labelling (ASL). A major advantage of ASL 
over DCE-MRI is that it does not need intravenous contrast 
material injection, which makes it an ideal tool for children. 
Magnetic resonance spectroscopy (MRS) allows for a non-
invasive separation of the MRI signal from a given tissue 
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Fig. 5  A 4-year-old girl 
diagnosed with stage IV neu-
roblastoma. Coronal acquired 
3D T2-weighted image (a) 
with axial reconstruction (c) 
demonstrates the primary 
tumour arising from the left 
adrenal gland (arrows) with 
compression upon the left kid-
ney, vascular encasement and 
lifting of the aorta (arrowhead). 
The post-contrast T1-weighted 
image illustrates heterogeneous 
enhancement (b). There is dif-
fusion restriction seen as high 
signal at the b1000 image (d) 
with corresponding low signal 
at the ADC map (e)
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into its different chemical components, which may improve 
lesion characterization and prediction of clinical outcome. 
Although ASL and MRS are already established techniques 
in neuroradiology, their possible role in (paediatric) malig-
nancies outside the brain has to be validated yet. In this 
scope, the recent development of integrated PET/MRI sys-
tems is very interesting, combining the superior structural 
imaging of MRI with the functional (molecular) informa-
tion of both imaging techniques while decreasing the radia-
tion dose. Although the first publications in children show 
promising results, it currently remains a technical challenge 
to construct and use these hybrid systems [51–53].
Conclusion
WB-MRI is a very promising and already widely used 
imaging technique in paediatric oncology. This is mainly 
due to the lack of ionising radiation, its superior tissue con-
trast and potential to non-invasively generate functional 
information on tumour biology. It provides complementary 
information to the increasingly used molecular imaging 
techniques like PET/CT and SPECT/CT. However, there 
is still a strong need for prospective large cohort studies to 
better validate the role and cost-effectiveness of WB-MRI 
in paediatric oncology.
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